Pharmaceuticals & Biopharmaceuticals

Melbourne – November 05, 2026 -- Telix Pharmaceuticals has joined Thera4Care, a 27-partner European consortium, and its FAP-targeting dimer DOTAGA.Glu.(FAPi)2 will enter a Phase 1 trial labelled with terbium-161 (161Tb) in metastatic solid tumors.

Consortium picks Telix's FAP dimer for a Phase 1 trial with terbium-161

The trial will assess the safety profile and preliminary activity of 161Tb-DOTAGA.Glu.(FAPi)2 in patients with FAP-expressing metastatic solid tumors. The initial focus is ovarian cancer, pancreatic cancer and sarcomas. Telix says this aligns closely with its own development plans for TLX400-Tx, the lutetium-177 (177Lu) version of the same compound. The dimer has already been validated in several clinical studies.

HONG KONG – November 05, 2026 -- Fosun has used its ninth consecutive China International Import Expo (CIIE) appearance to debut Intuitive Surgical's da Vinci 5 robotic system in China. It also reported that its Intuitive Fosun joint venture has trained more than 23,000 doctors across 33 training centers. This year's expo in Shanghai draws participants from 162 countries, regions and international organizations, with more than 4,100 corporate exhibitors.

Fosun is exhibiting at the Fosun Pharma booth (2.1C4-01) in the Medical Equipment and Healthcare Products Exhibition Area. Its displays cover oncology, immunology and inflammation, and neurodegenerative diseases. Fosun International Chairman Guo Guangchang described the CIIE as "an annual test of our global industrial and innovation capabilities."

Shanghai – November 05, 2026 -- Dizal (SSE: 688192) will present three oral and five poster presentations from its hematological disease portfolio at the 68th American Society of Hematology (ASH) Annual Meeting, including the first clinical data for its EZH1/2 inhibitor GW5282 in relapsed or refractory non-Hodgkin lymphoma (r/r NHL).

Golidocitinib data extend from lymphoma into secondary HLH

An oral presentation will report updated results for golidocitinib monotherapy in adults with secondary hemophagocytic lymphohistiocytosis (HLH). The data extend findings shown at the European Hematology Association (EHA) Congress 2026. Dizal reports high and durable response rates with a manageable safety profile, which it says supports further development in the indication.

Austin, Texas – November 05, 2026 -- Genprex (NASDAQ: GNPX) reported that whole-blood analysis of 11 lung cancer patients treated with its gene therapy REQORSA (quaratusugene ozeplasmid) showed a shift toward mitochondrial adaptation, autophagy and protein quality control 24 hours after infusion. The company presented the findings at the Gerontological Society of America (GSA) 2026 Annual Scientific Meeting, held November 4-7 in National Harbor, Maryland.

Blood samples from two REQORSA trials show a two-phase response

The patients were enrolled in two clinical trials evaluating REQORSA. Researchers collected whole-blood transcriptomes before treatment and at 5 and 24 hours after intravenous administration. They compared the 0-5, 5-24 and 0-24 hour intervals to separate the acute response to delivery from the sustained cellular-remodeling program.

Cantanhede – November 05, 2026 -- Mondego Bio has started a first-in-human Phase 1 study of MB-388, an oral dual PTPN2/PTPN1 inhibitor built to overcome resistance to cancer immunotherapy, with initial human pharmacokinetic and pharmacodynamic data due in December 2026.

Phase 1a tests dose escalation in healthy volunteers

The randomized, double-blind, placebo-controlled study will evaluate single and multiple ascending doses of MB-388. It will assess safety and tolerability, characterize pharmacokinetics and measure target engagement using blood-based pharmacodynamic biomarkers.

CEO Nikolay Savchuk said the study will define the relationship between exposure, pathway engagement and tolerability ahead of the planned patient study.

Gaithersburg – November 05, 2026 -- Novavax raised its full-year 2026 Non-GAAP Adjusted Total Revenue guidance by $145 million to $400 million at the mid-point, after earning a $125 million milestone from partner Sanofi and cutting its quarterly net loss to $31 million from $202 million a year earlier.

Sanofi's European Phase 3 start triggers $125 million payment

Novavax earned the payment in October, when Sanofi initiated a Phase 3 trial of its influenza-COVID-19 combination (CIC) vaccine in Europe. Sanofi has confirmed it intends to start a U.S. Phase 3 CIC trial in 2027 to support U.S. approval.

SARASOTA – November 05, 2026 -- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) paid $1,270,970 in cash to redeem all 127,097 remaining shares of its Series C Convertible Preferred Stock, leaving the clinical-stage company with no preferred equity outstanding.

Redemption with Shakawe Capital closes under a November 2 agreement

The transaction was executed under a redemption agreement dated November 2, 2026, with Shakawe Capital LLC. The company funded the payment from cash on hand.

Conversion dilution risk is eliminated

No Series C shares remain outstanding, so no additional common shares will be issuable upon conversion. The redemption also removes all restrictions tied to the instrument. Lakewood-Amedex reports no outstanding indebtedness for borrowed money.

CEO Kelvin Cooper said the move "simplifies our capital structure" and gives the company greater financial flexibility as it advances its development programs.

Valencia – November 04, 2026 -- ARTHEx Biotech, a clinical-stage RNA therapeutics developer, has appointed Christian (Chris) Freitag, M.D., as Chief Medical Officer, adding more than 20 years of clinical development experience to a pipeline led by ATX-01 for myotonic dystrophy type 1 (DM1).

Freitag arrives from CMO roles at Azafaros and Dynacure

Freitag most recently served as Chief Medical Officer at Azafaros, which develops treatments for rare genetic disorders. Before that, he was CMO at Dynacure, where he was responsible for medical and regulatory strategy, including clinical development of the company's lead investigational therapy for centronuclear myopathies.

Beijing – November 04, 2026 -- Gan & Lee Pharmaceuticals (Stock Code: 603087.SH) reported that once-monthly bofanglutide met the primary endpoint of its Phase IIIb GRADUAL-3 study, holding body weight near baseline over 24 weeks while the placebo group changed by 8.52%.

Both monthly dose groups beat placebo at P0.0001

Mean body-weight changes from baseline were 0.41% in the 24 mg once-monthly group and -0.12% in the 48 mg group, against 8.52% for placebo. Both comparisons reached P0.0001. The primary endpoint was the percentage change in body weight from baseline after 24 weeks.

San Diego – November 04, 2026 -- Circular Genomics and PharmatrophiX have launched a biomarker collaboration that applies blood-based circular RNA (circRNA) profiling to LM11A-31, PharmatrophiX's first-in-class Alzheimer's candidate, with possible extension across the company's neurodegeneration pipeline.

Planned open-label study is the first test of the circRNA platform

The initial workstream centers on PharmatrophiX's planned open-label Alzheimer's biomarker study of LM11A-31, a small molecule targeting the p75 neurotrophin receptor (p75NTR). Circular Genomics will use its research-use-only CircPath platform to characterize baseline molecular heterogeneity and track pathway-level changes during treatment.